BioPharm News

BioPharm International: Apr 30, 2015
The costs and benefits of integrating modular concepts for on-demand bioprocessing are explored.
BioPharm International: Apr 30, 2015
Choosing the optimal protein expression vector depends on strain, promoter, and a number of other factors.
Apr 29, 2015
By BioPharm International Editors
Perrigo rejected Mylan’s second proposal for an acquisition valued at more than $34 billion, saying that the offer was too low to consider.
Apr 28, 2015
By BioPharm International Editors
In a smoldering letter, Mylan’s executive chairman announced the unanimous rejection of a $40-billion unsolicited acquisition offer from Teva.
BioPharm International: Apr 27, 2015
By BioPharm International Editors
FDA releases long-awaited guidance documents regarding the assessment of biosimilarity.
Apr 26, 2015
By BioPharm International Editors
Innate Pharma announces a co-development and commercialization agreement with AstraZeneca to accelerate the development of Innate’s anti-NKG2A antibody.
Apr 23, 2015
By BioPharm International Editors
Dicerna Pharmaceuticals announces that FDA granted its primary hyperoxaluria type 1 (PH1) treatment Orphan Drug designation.
BioPharm International: Apr 23, 2015
By BioPharm International Editors
The agency has recommended granting marketing authorization for Opdivo.
Apr 22, 2015
By BioPharm International Editors
MaxCyte announces a strategic partnership with Johns Hopkins University to develop CAR T-Cell therapies for cancer.
BioPharm International: Apr 21, 2015
By BioPharm International Editors
INTERPHEX 2015 is under way and Pharmaceutical Technology and BioPharm International are in the middle of the action!